There have been several reports9, 11, 15, 16 of bilateral NSM for breast cancer risk reduction, but these focused only on patients with mutations in BRCA1 and BRCA2. In addition, many of these series report only short‐term oncological follow‐up. The gene discussed is BRCA1; the disease is breast carcinoma.